The aim of this study is to measure the efficacy (how well it works) and safety of efgartigimod compared with placebo (inactive substance) in participants with ocular myasthenia gravis (oMG). The study will also measure the long-term efficacy, safety, and tolerability of efgartigimod.

Have you been diagnosed with Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer? If so, you may be a good fit for a clinical trial to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab).

Do you have solid tumor of the lung or esophagus? Have the standard treatments for your condition been ineffective or not tolerable? If so, you may be eligible to participate in an early phase research study of the investigational drug YL201 as a possible treatment for advanced solid tumors.

Are you right-handed? Are you between the ages 18 and 35 or 65 and 85? Are you interested in testing your memory? If so, you may be able to take part in a study on how younger and older adults learn and remember objects. You can help us learn more about how memory works in adults! Compensation provided.

The purpose of this research is to see if an experimental vaccine, which is created from your tumor tissue and dendritic cells isolated from your blood, can be an effective therapy when given after your standard treatment of surgery, chemotherapy, and radiation.

Have you been diagnosed with anaplastic thyroid cancer? If so, you might be able to take part in a study to look at the effectiveness of taking cemiplimab and XL092 before and after surgery for your cancer.

Did you recently have an ACLR? Are you aware of your increase chances of developing knee osteoarthritis? If so, please participate in our study analyzing how knee joint movements are linked to cartilage strain to help prevent knee osteoarthritis. Compensation provided.

By doing this study, we hope to learn if the combination of belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone is effective and safe when given to persons with multiple myeloma that has gotten worse and is not responding to standard drugs that are used for treating multiple myeloma, including chimeric antigen receptor T-cell therapy.

In this study, we want to find out if a single therapy session that shows people how to deal with depression is effective.

To investigate people's social interactions in the context of their daily life.